Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07162194 · ClinicalTrials.gov registry record · NA
MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial
A NA study of Prostate Carcinoma, sponsored by University of Southern California.
- Recruiting
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 1
- Study location
NCT07162194 is a NA study of Prostate Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 130 participants, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07162194, a NA study of Prostate Carcinoma, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence \[AI\]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is performing a prostate MRI. An MRI uses a magnetic field to take pictures of the body. The MRI images are examined by a radiologist. If a suspicious area is seen in the MRI, the radiologist assigns it a PIRADS score. This stands for Prostate Imaging Reporting and Data System. The PIRADS score is used to report how likely it is that a suspicious area in the prostate is cancer. The AI system has been developed also to be able to analyze prostate MRI images and detect suspicious areas in the prostate that may be cancer. The AI system's ability to diagnose aggressive prostate cancer may be similar to detection performed by experienced radiologists using the standard PIRADS system of analyzing prostate MRI.
Conditions Studied
Interventions
- PROCEDURE Radical Prostatectomy
- PROCEDURE Targeted Prostate Biopsy
- DIAGNOSTIC_TEST Prostate Imaging Reporting & Data System
- DIAGNOSTIC_TEST Deep Learning Artificial Intelligence
- DIAGNOSTIC_TEST Green Learning Artificial Intelligence
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2028-10-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07162194
The ClinicalTrials.gov registry entry for NCT07162194 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,500-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Radical Prostatectomy is the first listed.
NCT07162194 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07162194 about?
NCT07162194 is a clinical study titled "MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial". This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence \[AI\]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is perf...
What is the current status of trial NCT07162194?
This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-09-19. Estimated completion is 2028-10-15.
What conditions does trial NCT07162194 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT07162194?
The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Targeted Prostate Biopsy (PROCEDURE), Prostate Imaging Reporting & Data System (DIAGNOSTIC_TEST), Deep Learning Artificial Intelligence (DIAGNOSTIC_TEST), Green Learning Artificial Intelligence (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07162194?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07162194 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
-
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
RECRUITING · NA
-
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
RECRUITING · NA
-
Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.